Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97382 | 0.84 | ALDH1A1 (0.34) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL2094066 | 0.77 | TUBB1 (0.32) | CYP3A4MAPK1TDP1POLB | |
| SCHEMBL98118 | 0.77 | ACHE (0.56) | ALDH1A1TDP1KMT2ALMNAMAPT | |
| SCHEMBL2092734 | 0.74 | ALDH1A1 (0.58) | ALDH1A1CYP3A4KMT2AMEN1POLB | |
| SCHEMBL95901 | 0.74 | ACHE (0.48) | ALDH1A1TSHRCYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL11866357 | 0.74 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| Carbon Dioxide SCHEMBL28275984 | 0.73 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL28135369 | 0.73 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL2096116 | 0.72 | RAPGEF4 (0.35) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL2496298 | 0.70 | CYP2A6 (0.54) | ALDH1A1TSHRCYP3A4TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387954-A1 | LONG-LIVED REDOX-ACTIVE MOLECULES WITH LOW REDOX POTENTIAL | President and Fellows of Harvard College (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240136561-A1 | ELECTRICAL REGENERATION OF ELECTROLYTES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-04-25 | — | — | US | disclosed |
| EP-4351662-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794585-A | Radioimmunoconjugates and checkpoint inhibitor combination therapies | 融合制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117603148-A | Pharmacokinetic enhancement of difunctional chelates and uses thereof | 探针技术开发及商业化中心 | 2024-02-27 | — | — | CN | disclosed |
| CN-117482261-A | Combination therapy of radioimmunoconjugates and checkpoint inhibitors | 融合制药公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4292156-A1 | ELECTRICAL REGENERATION OF ELECTROLYTES | President and Fellows of Harvard College (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4289950-A2 | MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF | Revolution Medicines, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-5837829-A | 9-oximesilyl erythromycin a derivatives | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0605149-B1 | Recording sheet | JUJO PAPER CO LTD (JP) | 1998-04-22 | — | — | EP | disclosed |
| US-5719272-A | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives | ABBOTT LABORATORIES (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1997036913-A1 | 9-OXIMESILYL ERYTHROMYCIN A DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036912-A1 | 2'-PROTECTED 3'-DIMETHYLAMINE, 9-ETHEROXIME ERYTHROMYCIN A DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-10-09 | — | — | WO | disclosed |
| US-5482913-A | CARBONATE TYPE BLOCKED COLOR DEVELOPER, LASER RECORDING | NIPPON PAPER INDUSTRIES, CO., LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| EP-0605149-A2 | Recording sheet | NIPPON PAPER INDUSTRIES CO., LTD. (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0158467-B1 | METHOD FOR SELECTIVE METHYLATION OF ERYTHROMYCIN A DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4672109-A | Method for selective methylation of erythromycin A derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1987-06-09 | — | — | US | disclosed |
| EP-0158467-A2 | Method for selective methylation of erythromycin a derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1985-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | CEP170, PIN1, FKBP3 | ALDH1A1 4800/4885TSHR 4480/4885CYP3A4 2870/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ALDH1A1 1969/4885TSHR 2428/4885CYP3A4 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.